ABL Lyon Information

What do all therapies under development have in common? Whether in preclinical or clinical stage, they all need robust and reliable biomarker monitoring tools to track and characterize their biological effect. ABL is a global leader in immunobiology, offering expert biomarker testing services to advance therapies from discovery to clinical stages. Our offer combines tens of years of clinical experience, the highest quality environment, and the largest panel of immunoassay technologies in Europe. Therapeutic areas include oncology, infectious diseases, inflammatory, auto-immune, or neurodegenerative conditions. High versatility: large menu of prequalified biomarkers or innovative customized assays. Using key technologies such as single-plex ELISA, multiplex Luminex immunoassays, ultra-sensitive immunoassays on SiMoA (Quanterix), Erenna (Singulex) or Circascan (Aushon) platforms, ELISpot, multi-parametric flow cytometry, other cell-based assays, and an international PBMC network, ABL offers multiple fit-for-purpose bioanalytical solutions and supports dozens of clinical trials.